Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 18/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 18/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ITGAV | P06756 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4832505 | 1.00 | ITGB3 (0.45) | ITGB3ITGA2BLMNAITGAV | |
| SCHEMBL4832623 | 0.92 | ITGB3 (0.46) | ITGB3ITGA2BLMNAITGAV | |
| SCHEMBL14306994 | 0.89 | MEN1 (0.41) | ITGB3ITGA2B | |
| SCHEMBL5174469 | 0.84 | ITGB3 (0.42) | ITGB3ITGA2BLMNAITGAV | |
| SCHEMBL14253141 | 0.84 | ITGB3 (0.41) | ITGB3ITGA2BITGAV | |
| SCHEMBL14316415 | 0.81 | ACACB (0.42) | — | |
| SCHEMBL7046619 | 0.81 | LMNA (0.48) | ITGB3ITGA2BLMNAITGAV | |
| SCHEMBL4835768 | 0.81 | ITGB3 (0.69) | ITGB3ITGA2BITGAV | |
| SCHEMBL5175196 | 0.76 | ITGB3 (0.43) | ITGB3ITGA2BLMNAITGAV | |
| SCHEMBL4834857 | 0.76 | ITGB3 (0.46) | ITGB3ITGA2BLMNAITGAV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7348333-B2 | Cycloalkyl derivatives as inhibitors of bone resorption and vitronectin receptor antagonists | AVENTIS PHARMA S.A. (FR) | 2008-03-25 | — | — | US | disclosed |
| US-20030050314-A1 | Novel cycloalkyl derivatives as inhibitors of bone resorption and vitronectin receptor antagonists | AVENTIS PHARMA S.A. | 2003-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030050314-A1 | Novel cycloalkyl derivatives as inhibitors of bone resorption and vitronectin receptor antagonists | ADGRF1, CALCRL, ADGRE5 | ITGB3 545/4885ITGA2B 384/4885LMNA 580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.